Form 4 for DGX Quest Diagnostics
Accepted 2025-02-14 00:00:00 ET · period of report 2025-02-12 · accession 0001022079-25-000032 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-14 | 2025-02-12 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $0.00 | +1,815 | 6,439 | +39% | $0 |
| D | 2025-02-14 | 2025-02-12 | DGX | DELANEY MARK E | SVP, Chief Commercial Off | A - Grant | $0.00 | +6,960 | 6,960 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-12 | A | A | 1,815 | $0.00 | 6,439 | D | — | — | (F1) Represents an award of restricted stock units. |
| 2 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-02-12 | A | A | 6,960 | $0.00 | 6,960 | D | $165.30 · — to 2035-02-12 | 6,960 Common Stock | (F2) The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. |